BMO recently hosted a conference call with leading Alzheimer’s disease researcher Dr. Dennis Selkoe to discuss the amyloid hypothesis and its potential implications for Eli Lilly and Co LLY 1.18%’s late-stage trials. According to analyst Alex Arfaei, Selkoe is cautiously optimistic about the prospects for Eli Lilly’s Solanezumab.

Selkoe believes that the future of AD treatment is likely combination therapy that involves treating a number of different drivers of the disease. While he believes that soluble AB oligomers are more harmful than plaques and should be the primary target for researchers, lowering plaques should also help lower oligimer levels as well. Plaques and oligimers typically remain in equilibrium in the brain.

Selkoe estimates a 60 percent chance of success for Solanezumab in Eli Lilly’s E3 testing. BMO is even more optimistic.

“We estimate…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!